

Dovato® (dolutegravir/lamivudine) – Expanded indication

- On August 6, 2020, ViiV Healthcare announced the FDA approval of Dovato (dolutegravir/lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.
 - Previously, Dovato was approved for the treatment of HIV-1 infection in adults with no ARV treatment history and no known substitutions associated with resistance to the individual components of Dovato.
- Dovato contains an integrase strand transfer inhibitor (dolutegravir) and a nucleoside analogue reverse transcriptase inhibitor (lamivudine).
- The approval of the expanded indication was based on TANGO, a 200-week, open-label, non-inferiority study enrolling 741 adult HIV-1-infected subjects who were on a stable suppressive tenofovir alafenamide-based regimen (TBR). Patients received Dovato or their current TBR. The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA ≥ 50 copies/mL (virologic non-response) at week 48.
 - In the primary analysis, < 1% of subjects in both arms experienced virologic non-response (HIV-1 RNA ≥ 50 copies/mL) at 48 weeks (treatment difference: -0.3%; 95% CI: -1.2%, 0.7%).
 - Based on a 4% non-inferiority margin, Dovato was non-inferior to TBR at week 48.
- Dovato carries a boxed warning for patients co-infected with hepatitis B virus (HBV) and HIV-1: emergence of lamivudine-resistant HBV and exacerbations of HBV.
- The recommended dose of Dovato for both indications is one tablet (dolutegravir 50 mg/ lamivudine 300 mg) taken orally once daily with or without food.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

 $\mbox{RxNews}^{\mbox{\tiny{\^{0}}}}$ is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.